SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AspenBio Pharma, Inc. (Note: Request metadata listed "Riot Platforms, Inc.", but the filing text identifies the registrant as AspenBio Pharma, Inc.)
Filing Date: January 24, 2007
Reporting Period: Current report for events occurring on January 24, 2007.
Business: The registrant is a Colorado corporation headquartered in Castle Rock, CO.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding executive compensation and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change reported is an amendment to the employment agreement for the company's President and CEO, Richard Donnelly.
- Executive: Richard Donnelly (President and CEO).
- Action: Execution of Amendment No. 1 to the Employment Agreement originally dated February 1, 2005.
- Compensation Change: The amendment establishes an initial two-year term with a base salary of $225,000.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on business outlook, specific risk factors, or contingencies beyond the disclosure of the executive compensation amendment under Regulation FD.
Investor Verification Checklist
- Verify the full terms of the employment amendment (Exhibit 10.25(a)) for details on bonuses, equity, or severance not summarized in the 8-K text.
- Confirm the current stock price and market capitalization to assess the impact of the $225,000 base salary relative to company valuation.
- Review recent 10-K or 10-Q filings for AspenBio Pharma, Inc. to obtain actual financial performance data, as this 8-K contains none.
- Clarify the discrepancy between the request metadata ("Riot Platforms, Inc.") and the filing registrant ("AspenBio Pharma, Inc.") to ensure the correct entity is being analyzed.